Bringing target-matched PI3King from the bench to the clinic


Increased signaling through the phosphoinositide 3-kinase (PI3K)/AKT/ mammalian target of rapamycin (mTOR) pathway occurs in diverse malignancies. In cancer, the PI3K/AKT/mTOR pathway can be activated by mutations in several oncogenes such as PIK3CA, PIK3R1, AKT, TSC1/2, LKB1 and PTEN (Fig. 1). Most activating mutations occur in the helical or kinase domain… (More)
DOI: 10.4161/cc.25118

1 Figure or Table


  • Presentations referencing similar topics